MedPath

Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS

Phase 4
Conditions
Infertility
Polycystic Ovarian Syndrome
Interventions
Registration Number
NCT02344888
Lead Sponsor
Mahmoud Thabet
Brief Summary

The purpose of this study is to evaluate the effect of concomitant administration of prednisolone during use of clomiphene citrate (CC) for induction of ovulation in infertile lean women having CC resistant polycystic ovarian syndrome (PCOS).

Detailed Description

Women will be randomly divided into two groups; CC-Prednisolone group and CC-placebo group. Women in the CC-Prednisolone group will receive CC (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone tablet (5 mg/day for 10 consecutive days from day 2 of the cycle). Women in the CC-placebo group will receive CC alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid tablet (0.5 mg/day for 10 consecutive days from day 2 of the cycle). Transvaginal sonography (TVS) scan will be performed regularly for monitoring of follicular growth (folliculometry); starting from day 10 of the stimulation cycle and repeated every 2-3 days. When there will be at least one follicle ≥ 18 mm in diameter, final oocyte maturation will be induced by intramuscular administration of 10000 IU of human chorionic gonadotropin (HCG) and timed intercourse will be advised. If there will be no follicle ≥ 12 mm by day 16 of the cycle, monitoring of follicular growth will be discontinued and the cycle will be presumed to be anovulatory. Ovulation will be documented by TVS scan one week after triggering of oocyte maturation and will be confirmed by assessing the mid-luteal serum progesterone level. Each woman will be subjected to ovarian stimulation for a maximum of 3 consecutive cycles except if she gets pregnant in the first or second cycle

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
300
Inclusion Criteria
  • Infertile lean women with PCOS as defined by the Rotterdam criteria.
  • CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles).
Exclusion Criteria
  • Age < 20 or > 35 years.
  • Body mass index (BMI) < 18.5 kg/m2 or > 25 kg/m2.
  • Presence of any infertility factor other than anovulatory PCOS.
  • Previous history of ovarian surgery or surgical removal of one ovary.
  • Previous exposure to cytotoxic drugs or pelvic irradiation.
  • Oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months.
  • Metabolic or hormonal abnormalities

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Clomiphene citrate-placebo groupClomiphene citrate and folic acidWomen will receive clomiphene citrate and folic acid 0.5mg (placebo)
Clomiphene citrate-Prednisolone groupClomiphene citrate and PrednisoloneWomen will receive clomiphene citrate and prednisolone
Primary Outcome Measures
NameTimeMethod
Ovulation rate3 months

Number of ovulatory cycles divided by the number of stimulation cycles

Secondary Outcome Measures
NameTimeMethod
Number of ovarian follicles ≥ 18 mm on day of HCG administration3 months

Number of ovarian follicles ≥ 18 mm by TVS on day of HCG administration

Endometrial thickness on day of HCG administration3 months

Endometrial thickness by TVS on day of HCG administration

Clinical pregnancy rate6-8 weeks gestational age

Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 6-8 weeks gestational age) divided by the number of women

Trial Locations

Locations (2)

Private practice settings

🇪🇬

Mansourah, Dakahlia, Egypt

Obstetrics and Gynecology Department in Mansoura University Hospital

🇪🇬

Mansourah, Dakahlia, Egypt

© Copyright 2025. All Rights Reserved by MedPath